← Eichor
Study identifier: NCT06918626 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

INtraoperative Approach With Eventual Clearance of Common bilE Duct by SpyGlass Discover vs Sequential Strategy in Patients With Acute Calculus Cholecystitis and Intermediate/High Risk of Common BiLE Duct Stone

Condition: Acute Calculous Cholecystitiis (ACC)  ·  Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

PhaseNA
Planned participants62
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

INACCESSIBLE trial is a randomized controlled study that compares two different strategies for the treatment of Acute Calculous Cholecystitiis (ACC) patients with high/intermediate risk of CBDS, according to the score by Khoury T (named Israelian Score, IS). If a patient meets the inclusion and exclusion criteria, (s)he will be randomized to receive ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures (control group) or ELC + Spyglass cholangiography (study group). The follow-up will be performed after 30 days and 6 months from intervention with an outpatient medical examination

This description comes directly from the study's public registry record.

Talk to the study team

Luca Ansaloni, MD  ·  +39 0382 50 2530  ·  l.ansaloni@smatteo.pv.it

Always discuss trial participation with your own doctor first.

Locations (1)

Fondazione IRCCS Policlinico San MatteoPavia, Pavia, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06918626